Cat. No.: HY-N0723

Neomangiferin

1 Cited Publications

Avis client

Based on 1 publication(s) in Google Scholar

Neomangiferin is an orally active natural flavonoid. Neomangiferin partially ameliorates non-alcoholic fatty liver disease (NAFLD) by regulating the expression of genes related to free fatty acid uptake and lipid oxidation. Neomangiferin exerts anti-colitis effects by inhibiting Th17/Treg cell differentiation. Neomangiferin exerts anti-aging and lifespan-extending effects by targeting upregulation of bas-1, which in turn activates the autophagy, IIS and MAPK pathways. Neomangiferin has the potential to prevent aseptic loosening of prostheses after total joint arthroplasty due to its significant anti-inflammatory and osteoclastogenesis-inhibiting effects.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.80%
CAS No.: 64809-67-2
Formule: C₂₅H₂₈O₁₆
Masse moléculaire:584.48

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Neomangiferin Chemical Structure

CAS No.: 64809-67-2

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform p38 MAPK :

Voir tous les produits spécifiques à Isoform TNF Receptor :

Voir tous les produits spécifiques à Isoform Interleukin Related :

Voir tous les produits spécifiques à Isoform PPAR :

In Vitro

Neomangiferin (5, 10, 20 μM; 5 days) suppresses TGFβ/IL-6-induced Th17 cell differentiation in purified splenic CD4⁺ T cells from C57BL/6J mice, reducing IL-17 and RORγt expression^[2].
Neomangiferin (5, 10, 20 μM; 5 days) promotes anti-CD3/anti-CD28-induced Treg cell differentiation in purified splenic T cells from C57BL/6J mice, increasing IL-10 expression^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Neomangiferin (25-50 mg/kg; oral gavage; daily administration; for 13 consecutive weeks) significantly ameliorates high-fat diet-induced non-alcoholic fatty liver disease (NAFLD) in male SD rats via reducing body fat and hepatic lipid accumulation, normalizing serum and hepatic lipid as well as antioxidant parameters, improving glucose tolerance and metabolic rate, and regulating the expression of genes and proteins related to fatty acid uptake and oxidation in the liver^[1].
Neomangiferin (10-20 mg/kg; p.o.; once daily; for 3 consecutive days) ameliorates TNBS-induced colitis in male C57BL/6J mice by inhibiting proinflammatory cytokine production and restoring the Th17/Treg balance; at the dose of 20 mg/kg, it inhibits myeloperoxidase activity by 73.9% and reduces IL-17 levels by 63.6%^[2].
Neomangiferin (20 mg/kg; p.o.; daily; for 3 consecutive weeks) improves spontaneous chronic colitis in male C57BL/6 IL-10 knockout mice by reducing the production of proinflammatory cytokines, inhibiting myeloperoxidase activity by 52.6%, and restoring the Th17/Treg balance^[2].
Neomangiferin (2.5-5 mg/kg, i.p., once every other day for 21 consecutive days) dose-dependently inhibits UHMWPE particle-induced inflammatory calvarial osteolysis in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley (SD) (male, 7-week-old, 200 g, high-fat diet-induced NAFLD)^[1]
Dosage:

50 mg/kg·day^-1 BW; 25 mg/kg·day^-1 BW
Administration:

oral gavage; daily; 13 weeks
Result:

Significantly decreased body weight compared to HF control group after 3 weeks of treatment; by week 8, reduced body weight to normal control levels with high-dose treatment.
Significantly lowered relative weights of organs (liver, spleen, testicle, brain, heart) and adipose tissues (abdominal, perirenal, subcutaneous, epididymal fat) with high-dose treatment compared to HF control group.
Reduced serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT), aspartate aminotransferase (AST), AST/ALT ratio, glucose (GLU), and D-3-hydroxybutyric acid (D-3H) levels, and increased serum high-density lipoprotein cholesterol (HDL-C) levels and HDL-C/TC ratio after 13 weeks of treatment compared to HF control group.
Decreased hepatic TG, TC, and malondialdehyde (MDA) levels, and increased hepatic superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX) levels compared to HF control group.
Increased fecal TG and TC levels compared to HF control group.
Reduced liver fat content from 43.6% (HF control) to a statistically significant lower level, decreased body fat content, and restored brown adipose tissue size with high-dose treatment compared to HF control group.
Significantly reduced hepatic fatty droplets, lipid accumulation, and renal lipid droplet accumulation compared to HF control group.
Lowered blood glucose levels at 30, 60, 90, and 120 minutes post-glucose gavage, and reduced glucose area under the curve (AUC) compared to HF control group.
Increased respiratory exchange rate (RER), oxygen consumption (VO₂), and carbon dioxide production (VCO₂) with high-dose treatment compared to HF control group, correcting diurnal metabolic rhythm defect.
Upregulated hepatic mRNA and protein expression of peroxisome proliferator-activated receptor α (PPARα) and carnitine palmitoyltransferase 1a (CPT1a), and downregulated hepatic mRNA and protein expression of fatty acid transport protein 2 (FATP2) and long-chain-fatty-acid-CoA ligase 1 (ACSL1) after 13 weeks of treatment compared to HF control group.

Animal Model:

C57BL/6J (male, 6 weeks old, 20-23 g, TNBS-induced colitis)^[2]
Dosage:

10 mg/kg; 20 mg/kg
Administration:

p.o.; daily; 3 days
Result:

Inhibited TNBS-induced colon shortening.
Reduced macroscopic colitis scores.
Suppressed myeloperoxidase activity by 73.9% (20 mg/kg dose).
Prevented TNBS-induced reduction in tight junction proteins ZO-1, occludin, and claudin-1.
Inhibited TNBS-induced ERK phosphorylation, NF-κB activation, and expression of inducible nitric oxide synthase and cyclooxygenase-2.
Reduced colon tissue levels of TNF-α by 45.5%, IL-1β by 78.1%, IL-17 by 63.6%, and IL-6 by 85.5%, while increasing IL-10 expression (20 mg/kg dose).
Inhibited TNBS-induced Th17 cell differentiation in colonic lamina propria and increased Treg cell differentiation.
Attenuated TNBS-mediated upregulation of IL-17, IFN-γ, RORγt, and T-bet mRNA, and restored TNBS-suppressed IL-10, IL-5, Foxp3, and GATA3 mRNA expression.

Animal Model:

C57BL/6 IL-10 knockout (male, 13 weeks old at treatment initiation, 18-21 g, spontaneous chronic colitis)^[2]
Dosage:

20 mg/kg
Administration:

p.o.; daily; 3 weeks
Result:

Reduced colonic myeloperoxidase activity by 52.6%.
Improved histopathological severity of colitis.
Increased expression of tight junction proteins ZO-1, occludin, and claudin-1.
Inhibited infiltration of antigen-presenting cells.
Suppressed ERK phosphorylation, NF-κB activation, and expression of inducible nitric oxide synthase and cyclooxygenase-2.
Reduced colon tissue levels of TNF-α by 17.3%, IL-1β by 54.5%, IFN-γ by 27.8%, and IL-17 by 52.8%.
Inhibited Th17 cell differentiation in colonic lamina propria and increased Treg cell differentiation.
Suppressed IL-17 and RORγt mRNA expression.

Animal Model:

C57BL/6 (8-week-old male, specific pathogen free grade, UHMWPE particles implanted into calvarial subperiosteal space)^[3]
Dosage:

2.5 mg/kg; 5 mg/kg
Administration:

i.p.; every other day; 21 days
Result:

Significantly increased bone mineral density (BMD) and bone volume/tissue volume ratio (BV/TV), and decreased the number of bone resorption pits and total skull porosity compared to the vehicle group, with 5 mg/kg group showing greater improvement than 2.5 mg/kg group.
Significantly reduced the number of TRAP-positive osteoclasts and the area of calvarial bone erosion compared to the vehicle group, with 5 mg/kg group showing greater reduction than 2.5 mg/kg group.
Significantly reduced serum levels of TNF-α, IL-1β, RANKL, OSCAR, and CTX-1, and increased serum OPG levels compared to the vehicle group, with 5 mg/kg group showing greater reductions in proinflammatory cytokines and osteoclast markers, and greater increase in OPG, than 2.5 mg/kg group.

Chemical Information

CAS No. 64809-67-2
Appearance Solid
Masse moléculaire 584.48
Formule C₂₅H₂₈O₁₆
Color White to light yellow
SMILES

OC1=C(C2=O)C(OC3=CC(O)=C(O[C@@H]([C@@H]([C@@H](O)[C@@H]4O)O)O[C@@H]4CO)C=C23)=CC(O)=C1[C@@H]([C@@H]([C@@H](O)[C@@H]5O)O)O[C@@H]5CO
Structure Classification
- Phenols
- Polyphenols
- Phenols
- Xanthones
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Chin Med

Therapeutic potential of Sheng-Xian-Tang in doxorubicin-induced chronic heart failure by regulation of phenylalanine metabolism disruption. [Abstract]

2026 Jan 12;21(1):29. PMID: 41527105

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (171.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7109 mL

8.5546 mL

17.1092 mL

5 mM

0.3422 mL

1.7109 mL

3.4218 mL

10 mM

0.1711 mL

0.8555 mL

1.7109 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.28 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (288 KB)
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Zhou C, et al. Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats. Int Immunopharmacol. 2015;25(1):218-228. [Content Brief]

[2]. Lim SM, et al. Neomangiferin modulates the Th17/Treg balance and ameliorates colitis in mice. Phytomedicine. 2016;23(2):131-140. [Content Brief]

[3]. Wang HT, et al. A study on the prevention and treatment of murine calvarial inflammatory osteolysis induced by ultra-high-molecular-weight polyethylene particles with neomangiferin. Exp Ther Med. 2018;16(5):3889-3896. [Content Brief]

[4]. Wu M, et al. Neomangiferin prolongs the lifespan of Caenorhabditis elegans by regulating autophagy-dependent IIS and MAPK pathways via bas-1. Food & Function. 2025;16(19):7690-704.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7109 mL	8.5546 mL	17.1092 mL	42.7731 mL
	5 mM	0.3422 mL	1.7109 mL	3.4218 mL	8.5546 mL
	10 mM	0.1711 mL	0.8555 mL	1.7109 mL	4.2773 mL
	15 mM	0.1141 mL	0.5703 mL	1.1406 mL	2.8515 mL
	20 mM	0.0855 mL	0.4277 mL	0.8555 mL	2.1387 mL
	25 mM	0.0684 mL	0.3422 mL	0.6844 mL	1.7109 mL
	30 mM	0.0570 mL	0.2852 mL	0.5703 mL	1.4258 mL
	40 mM	0.0428 mL	0.2139 mL	0.4277 mL	1.0693 mL
	50 mM	0.0342 mL	0.1711 mL	0.3422 mL	0.8555 mL
	60 mM	0.0285 mL	0.1426 mL	0.2852 mL	0.7129 mL
	80 mM	0.0214 mL	0.1069 mL	0.2139 mL	0.5347 mL
	100 mM	0.0171 mL	0.0855 mL	0.1711 mL	0.4277 mL

Neomangiferin

1 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Neomangiferin

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Anti-diabetic Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Phenols Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Lung Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Nuclear Receptor Compound Library

Osteogenesis Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Cell Death Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Neomangiferin

Voir tous les produits spécifiques à Isoform p38 MAPK

Voir tous les produits spécifiques à Isoform TNF Receptor

Voir tous les produits spécifiques à Isoform Interleukin Related

Voir tous les produits spécifiques à Isoform PPAR

Activité biologique

Chemical Information

Publications (1)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Neomangiferin Related Classifications

HY-N0723 Related Classifications